Toxicity and appropriate targeting are challenges for small molecule researchers
Search results for: Biologics
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
How Rheumatologists Can Win Support and Influence Congress
Ways to use the ACR’s advocacy toolkit to contact Congressional representatives and articulate your message to lawmakers
Prednisone Might be the Missing Ingredient in the American College of Rheumatology’s Recommendations for Treating Patients with Rheumatoid Arthritis
A combination therapy with glucocorticoids may be the gold standard for treating patients with rheumatoid arthritis (RA)
ACR/ARHP Annual Meeting 2012: Federal Act Aims to Make New Biologic Drugs Available to Rheumatology Patients at a Lower Cost
The Biologics Price Competition and Innovation Act of 2009 would spur the development of products intended to be biosimilar to approved therapies
Rheumatology Chooses Wisely
ACR identifies five practices, therapies, or procedures physicians and patients should question
Panel Addresses Drug Safety Issues in Rheumatology Products
Black box warnings, TNF inhibitors, and tofacitinib discussed
ACR Leaders Converge on Capitol Hill
American College of Rheumatology (ACR) members to discuss legislation and regulatory issues facing rheumatologists at this year’s annual ACR Advocacy Leadership Conference in Washington, D.C.
ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
People with rheumatic diseases can be considered to receive flu and pneumococcal vaccines even if they’re on immunosuppressive drugs
Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis
A new study confirms that the use of immunosuppressive drugs is associated with a reduced risk of vision loss in patients with juvenile idiopathic arthritis-related uveitis.
- « Previous Page
- 1
- …
- 65
- 66
- 67
- 68
- 69
- …
- 76
- Next Page »